Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations

Stopped early · Not applicable

Conditions studied: BRCA1 Mutation, Breast Cancer

In brief

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of recombinant human chorionic gonadotropin may prevent breast cancer in premenopausal women with BRCA1 mutations. PURPOSE: This clinical trial is studying recombinant human chorionic gonadotropin in preventing breast cancer in premenopausal women with BRCA1 mutations.

Key facts

Study ID

NCT00700778

Run by

Fox Chase Cancer Center

People needed

2

Starts

2008-07-01

Expected to finish

2014-03-01

Last updated by the study team

2021-01-25

Who can join

Age: 20 and older, up to 40. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Mayo Clinic Cancer Center — Rochester, Minnesota, United States
• Fox Chase Cancer Center - Philadelphia — Philadelphia, Pennsylvania, United States
• Universitaetsklinik fuer Frauenheilkunde — Vienna, Austria

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.